pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Dana-Farber Cancer Institute Inc

updated 6mo ago
community read0 votes

🐶 often sniffed alongside

top 4
  • tagOncology3 co-mentions · 1 sources
  • tagHepatology1 co-mentions · 1 sources
  • drugatezolizumab1 co-mentions · 1 sources
  • drugTECENTRIQ1 co-mentions · 1 sources
pipeline
0
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(0)

no pipeline products on record

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Dana-Farber Cancer Institute Inc jobs →

News

  • National Academies report calls for faster decisions on publication retractions and corrections
    The National Academies urged the scientific community to respond more aggressively to claims of errors or manipulated data in published research
    stat · 2h ago
  • The persisting paradox of men’s health
    A new series in The Lancet argues for the need to investigate a paradox of men’s health: why men experience worse health outcomes than women, even though they hold undeniable…
    stat · 20d ago
  • STAT+: New atlas of colorectal tumors sheds light on why cancers in young people are more dangerous
    A new atlas of colorectal tumors sheds light on why cancers in young people are more dangerous.
    stat · 21d ago
  • ESMO 2026: Amgen’s Imdelltra slashes death risk by nearly 60% in small cell lung cancer
    When used alongside AstraZeneca’s Imfinzi, the bispecific T cell engager Imdelltra extended survival by eight months versus Imfinzi alone in Phase 3 study testing the combo in a first-line maintena…
    biospace · 24d ago
  • STAT+: Dana-Farber, Beth Israel to begin construction of new $1.68 billion cancer hospital
    Dana-Farber Cancer Institute and Beth Israel Lahey Health are starting work on a $1.68 billion cancer hospital in Boston, marking a new phase in their competition with Mass General Brigham.
    stat · 1mo ago
  • Rare EGFR mutation increases lung cancer risk 62 times in never smokers
    A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
    fiercebiotech · 2mo ago
  • STAT+: Top Boston hospitals clash over Medicare Advantage network after split
    First, Mass General Brigham split with Dana-Farber. Now its Medicare Advantage plan is dropping the cancer hospital.
    stat · 2mo ago
  • STAT+: As young people increasingly get cancer, new fertility options are changing their futures
    New technologies, cancer doctors, and reproductive specialists are working to give more patients a chance to have children post-treatment.
    stat · 3mo ago
  • #ASCO26: Personalized cancer vaccines may help brain cancer patients live longer
    Personalized cancer vaccines might make notoriously deadly brain cancers more susceptible to immunotherapy and possibly prolong survival for some patients, according to new research from the Dana-F…
    endpoints · 5mo ago
  • Bristol Myers unveils data for one of its next-gen blood cancer drugs
    Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
    biopharma_dive · 5mo ago
view all news mentions →
identifiers
source
globaldata
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?